A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
December 27, 2021 (Issue: 1640)
The FDA has approved Trudhesa (Impel Neuropharma),
a new dihydroergotamine nasal spray
product, for acute treatment of migraine with or
without aura in adults. Another dihydroergotamine
nasal spray (Migranal, and generics) has been
available for...more
- Drugs for migraine. Med Lett Drugs Ther 2020; 62:153.
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59:1.
- SD Silberstein et al. Dihydroergotamine (DHE) – then and now: a narrative review. Headache 2020; 60:40.
- SB Shrewsbury et al. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD) device, in healthy adult subjects. Headache 2019; 59:394.
- TR Smith et al. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache 2021; 61:1214.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
Article code: 1640c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
